ACURX PHARMACEUTICALS INC (ACXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.42+1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Acurx aims to expand its ibezapolstat program into recurrent C. difficile infection. Executives cut salaries to align leadership costs. The company raised capital through unregistered equity sales in April 2026. Analysts expect EPS losses to improve from -$2.39 in 2026 to -$2.13 in 2027.
Acurx remains loss-making with no revenue forecasted through 2027. Recent share price dropped 59% from highs. Litigation and negative capital allocation news add risks. EPS losses are still deep at -$1.97 for 2026 and worsening in 2027.
The market is selling off the stock sharply, reflecting high risk and ongoing losses. There is no clear consensus revenue growth or fair value, indicating uncertainty. Our view is cautious given the lack of revenue and persistent losses despite some management efforts.
Breaks if: failure to raise capital or dilution worsens
The company engaged in unregistered sales of equity securities as part of its capital allocation strategy.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened, as recent financial performance has declined significantly.
The market appears to be pricing in high risk due to ACXP's loss-making status and weak recent performance. There is an expectation that the broader healthcare sector will continue to provide some support, but this is uncertain.
Fundamentals are likely to remain under pressure in the near term, given the company's loss-making status and mixed management priorities. The probability of missing earnings is relatively high, which adds to the uncertainty.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, which could influence ACXP's trajectory. Additionally, broader economic conditions, particularly job growth, will be critical in determining the company's performance.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped to the bottom half of its industry. This change indicates the reason to own ACXP has weakened. The company is expanding its ibezapolstat program into rCDI, which is positive. However, the outlook for the next quarter shows a high miss probability of 52%.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$2.13 in FY27
Breaks if: progress score falls below 40%
Management plans to expand the ibezapolstat program into recurrent Clostridioides difficile infection (rCDI).
Breaks if: salary reductions reversed
The company has implemented salary reductions for executive officers as part of broader leadership compensation alignment measures.
Over the next 1 to 3 years, ACXP's outlook is clouded by high risk and mixed signals from management and the sector. Not investment advice.